Study Notes on Hypercalcemia and Hypocalcemia

INTRODUCTION

• Calcium is the most abundant mineral in the human body.

• Physiological functions of calcium:

  • Provides structural strength to the skeleton as hydroxyapatite salt $Ca<em>{10}(PO</em>{4})<em>{6}(OH)</em>{2}$.

  • Involved in cellular signaling and hormone secretion.

  • Contributes to cardiac pacemaker rhythmicity and contractility.

  • Essential for skeletal muscle contractility.

  • Plays a role in immune function and neural signaling.

• Calcium concentrations are tightly regulated:

  • Intracellular calcium concentration is very dynamic, regulated on timescales of milliseconds.

  • Extracellular calcium concentration is more stable, regulated on minutes to hours.

• Serum calcium concentrations maintained within a narrow range (8.5–10.5 mg/dL or 2.1–2.6 mM) through feedback mechanisms involving parathyroid hormone (PTH) and vitamin D metabolites $1,25(OH)_{2}D$ and $25(OH)D$.

• Main regulatory feedback mechanism:

  • PTH increases osteocyte production of RANKL, stimulating osteoclast-mediated bone resorption to mobilize skeletal calcium.

  • Feedback mechanisms involve parathyroid glands, kidney, intestine, and bone to control extracellular calcium.

HYPERCALCEMIA

ETIOLOGY

• Causes of hypercalcemia:

  • Primary hyperparathyroidism (pHPT) and malignancy are the most common causes.

  • In pHPT, excess PTH is produced without appropriate suppression by serum calcium.

  • pHPT often caused by nonmalignant growths (adenoma or hyperplasia) in parathyroid glands, which leads to increased parathyroid cell mass.

  • Genetic causes identified in about 30% of pHPT cases, often involving mutations in cyclin D1 or menin.

  • In FHH (familial hypocalciuric hypercalcemia), inactivating mutations in the CASR gene are often involved, leading to inappropriate PTH secretion.

  • In malignancies, many solid tumors produce PTH-related peptide (PTHrP) which mimics PTH effects, causing hypercalcemia.

  • Lymphoma and granulomatous diseases trigger hypercalcemia through extrarenal conversion of $25(OH)D$ to $1,25(OH)_{2}D$ by macrophage activity, enhancing intestinal absorption of calcium.

  • Causal mechanisms also include dehydration, immobilization, and certain dietary patterns like ketogenic diets.

CLINICAL MANIFESTATIONS

• Mild hypercalcemia (10.5–11.9 mg/dL):

  • Largely asymptomatic; may present with vague neuropsychiatric symptoms like concentration issues, fatigue, and weakness.

• Moderate to severe hypercalcemia (≥12–14 mg/dL):

  • Can lead to lethargy, stupor, nausea, vomiting, constipation, and urinary issues like nephrolithiasis.

  • Significant cardiac changes may occur (e.g., bradycardia, QRS widening).

DIAGNOSTIC APPROACH

• Initial evaluation should correct for albumin effects, measuring total serum calcium and albumin.

• PTH levels crucial in diagnosis; low PTH indicates hypoparathyroidism, while increased or appropriate PTH correlates with malignant causes.

• Seek history of medications, supplements, and past medical history.

• Urinary calcium can differentiate FHH from pHPT and establish the diagnosis.

TREATMENT OF HYPERCALCEMIA

• For mild, asymptomatic hypercalcemia:

  • Maintain hydration and monitor without urgent intervention.

• For significant hypercalcemia:

  • Start IV saline infusion (4–6 L over 24 hours) for volume expansion to enhance renal perfusion and calciuresis.

  • Use aminobisphosphonates (e.g., zoledronic acid, pamidronate) to decrease bone resorption effectively.

  • Calcitonin can provide rapid reduction in calcium levels in conjunction with hydration and aminobisphosphonates.

  • Denosumab may be used in refractory cases; glucocorticoids can assist with vitamin D-related hypercalcemia.

HYPOCALCEMIA

ETIOLOGY

• Causes can be classified by PTH levels:

  • Low PTH (hypoparathyroidism) involves conditions like parathyroid damage from surgery or autoimmune disorders.

  • High PTH (secondary hyperparathyroidism) often from vitamin D deficiency or chronic kidney disease.

CLINICAL MANIFESTATIONS

• Symptoms range from mild to life-threatening complications:

  • Moderate to severe hypocalcemia may cause parasthesias, cramps, seizures, bronchospasm, and cardiac issues.

  • Chvostek’s and Trousseau's signs indicate neuromuscular irritability.

DIAGNOSTIC APPROACH

• Measure serum calcium, albumin, phosphorus, and magnesium levels.

• Differentiate potential causes based on PTH levels and underlying health history.

TREATMENT OF HYPOCALCEMIA

• Severe cases require intravenous administration of calcium gluconate with telemetry monitoring.

• Chronic hypoparathyroidism treated with oral calcium supplements and calcitriol.

• Vitamin D deficiencies managed with supplementation based on severity and underlying causes.

GLOBAL CONSIDERATIONS

• Limited healthcare access results in advanced presentations of conditions like pHPT.

• Chronic diseases impacting mineral balance, such as vitamin D deficiency, remain critical concerns in various countries.

ACKNOWLEDGMENT

• The author acknowledges Dr. Sundeep Khosla's contributions in prior editions of the text.

FURTHER READING

• Specific studies and guidelines provided for deeper reading into hypercalcemia and hypocalcemia management and research developments.

• Definition of Terms

  • Total Serum Calcium: The sum of ionized calcium, calcium bound to proteins (primarily albumin), and calcium complexed with anions.

  • Ionized Calcium ($Ca^{2+}$): The physiologically active, unbound form of calcium that is regulated by the body’s feedback systems.

  • Hydroxyapatite: The crystalline mineral complex ($Ca<em>{10}(PO</em>{4})<em>{6}(OH)</em>{2}$) that provides structural integrity to the skeletal system.

• Epidemiology

  • Hypercalcemia is most frequently encountered as primary hyperparathyroidism (pHPT) in the outpatient setting and as malignancy-associated hypercalcemia in hospitalized patients.

  • Hypocalcemia is common in post-surgical patients (thyroid/parathyroid surgery) and individuals with advanced chronic kidney disease or severe Vitamin D deficiency.

• Pathophysiology

  • Hypercalcemia: Results from excessive calcium entry into the extracellular fluid (ECF) via bone resorption, intestinal absorption, or renal reabsorption, often driven by autonomous PTH secretion or mimicry by PTHrP.

  • Hypocalcemia: Occurs when PTH or vitamin D action is insufficient to maintain ECF calcium levels, or when calcium is lost to the extravascular space (e.g., pancreatitis or rapid bone mineralization).

• Disease Etiology

  • Hypercalcemia: Primary hyperparathyroidism (adenoma/hyperplasia), malignancy (humoral PTHrP or osteolytic lesions), sarcoidosis (excessive $1,25(OH)_{2}D$ production), and medications like thiazides or lithium.

  • Hypocalcemia: Hypoparathyroidism (post-surgical or autoimmune), Vitamin D deficiency, hypomagnesemia (inhibits PTH release/action), and hyperphosphatemia.

• Clinical Presentation

  • Hypercalcemia: Neuropsychiatric (fatigue, lethargy), gastrointestinal (constipation, nausea), renal (polyuria, nephrolithiasis), and cardiac (shortened $QT$ interval).

  • Hypocalcemia: Neuromuscular irritability (paresthesias, cramps, tetany), seizures, bronchospasm, and cardiac rhythm issues (prolonged $QT$ interval).

• Approach to Diagnosis

  • Step 1: Correct the measured total calcium for the serum albumin level.

  • Step 2: Measure the PTH level to categorize the disorder as PTH-mediated or non-PTH-mediated.

  • Step 3: Use secondary labs (phosphorus, magnesium, Vitamin D metabolites, urinary calcium) to narrow the differential.

• Workup and Expected Lab Results

  • Primary Hyperparathyroidism: High $Ca$, High $PTH$, Low $Phosphorus$, High-normal urinary calcium.

  • Malignancy (Humoral): High $Ca$, Low $PTH$, High $PTHrP$.

  • Hypoparathyroidism: Low $Ca$, Low $PTH$, High $Phosphorus$.

  • Secondary Hyperparathyroidism (Vitamin D deficiency): Low/Normal $Ca$, High $PTH$, Low $25(OH)D$.

• Treatment

  • Hypercalcemia: Isotonic saline infusion for volume expansion, IV aminobisphosphonates (e.g., zoledronic acid), calcitonin for rapid response, and denosumab for refractory malignancy cases.

  • Hypocalcemia: Acute symptomatic cases require IV calcium gluconate; chronic cases managed with oral calcium supplements and calcitriol.

• Clinical Pearls

  • Albumin Correction: For every $1.0 g/dL$ drop in albumin below $4.0 g/dL$, the total calcium drops by approximately $0.8 mg/dL$, though the ionized calcium may remain normal.

  • Magnesium Link: Hypomagnesemia can cause "refractory" hypocalcemia; the calcium will not normalize until the magnesium deficit is corrected because magnesium is required for PTH secretion.

  • Signs: Look for Chvostek’s sign (facial twitching) and Trousseau’s sign (carpal spasm) in hypocalcemia.

• Summary

  • Calcium balance is maintained through a tightly regulated feedback loop involving the parathyroid glands, kidneys, bone, and intestines. Diagnosis hinges on interpreting PTH levels in the context of corrected serum calcium, while treatment focuses on addressing the underlying etiology and stabilizing neuromuscular and cardiac excitability.

• Definition of Terms

  • Total Serum Calcium: Represents the combined concentration of ionized calcium (physiologically active), protein-bound calcium (primarily to albumin), and calcium complexed with anions like phosphate and citrate.

  • Ionized Calcium ($Ca^{2+}$): The physiologically active, unbound fraction (approx. 50% of total) that is tightly regulated by the Calcium-Sensing Receptor (CASR) on the parathyroid glands.

  • Hydroxyapatite: The crystalline mineral form of calcium phosphate ($Ca<em>{10}(PO</em>{4})<em>{6}(OH)</em>{2}$) that provides structural rigidity and serves as a reservoir for calcium and phosphorus.

  • PTHrP (Parathyroid Hormone-related Protein): A peptide often secreted by tumors that mimics the action of PTH at the PTH1R receptor, resulting in hypercalcemia.

• Epidemiology

  • Hypercalcemia: Affects roughly 0.1-1.0% of the population. Primary Hyperparathyroidism (pHPT) is the most common cause in non-hospitalized patients (often asymptomatic women). Malignancy is the leading cause in hospitalized patients, associated with poor prognosis.

  • Hypocalcemia: Frequently observed in clinical settings such as post-thyroidectomy (transient or permanent), advanced Chronic Kidney Disease (CKD), and critically ill patients (e.g., sepsis or pancreatitis).

• Pathophysiology of Hypo and Hypercalcemia

  • Hypercalcemia: Arises when the entry of calcium into the extracellular fluid (ECF) exceeds renal clearance. Mechanisms include:

    • Increased Bone Resorption: Enhanced osteoclast activity (PTH or PTHrP mediated).

    • Increased Intestinal Absorption: Excessive calcitriol generation (Vitamin D toxicity or granulomatous disease).

    • Decreased Renal Excretion: Increased tubular reabsorption of calcium (often due to PTH effect or thiazides).

  • Hypocalcemia: Occurs when regulatory mechanisms fail to maintain ECF calcium. Mechanisms include:

    • Failure of PTH/Vitamin D: Hypoparathyroidism or Vitamin D deficiency stops the mobilization of calcium from bone and gut.

    • Deposition/Chelation: Calcium is lost from the ECF into bone (hungry bone syndrome) or soft tissues (pancreatitis/saponification).

• Disease Etiology of the Electrolyte Abnormalities

  • Hypercalcemia:

    • Primary Hyperparathyroidism: Solitary adenoma (80%), hyperplasia (15%), or carcinoma (1%). Associated with MEN1, MEN2A, and 30% involve mutations in cyclin D1 or menin.

    • Malignancy: Squamous cell carcinomas (lung, esophagus), breast cancer, and multiple myeloma.

    • Vitamin D Excess: Over-supplementation or extra-renal conversion of $25(OH)D$ to $1,25(OH)_{2}D$ in sarcoidosis or lymphoma.

  • Hypocalcemia:

    • Hypoparathyroidism: Post-surgical damage, autoimmune destruction (APS1), or infiltrative diseases (hemochromatosis).

    • Secondary Hyperparathyroidism: CKD (failure to produce calcitriol), Vitamin D deficiency (malnutrition or malabsorption), and loop diuretics.

• Clinical Presentation

  • Hypercalcemia: Classically "Stones, Bones, Abdominal Groans, and Psychic Moans."

    • Renal: Nephrolithiasis, polyuria/polydipsia via nephrogenic diabetes insipidus.

    • Neurologic: Fatigue, depression, confusion, and lethargy.

    • Cardiac: Shortened $QT$ interval, bradycardia, and increased sensitivity to digitalis.

  • Hypocalcemia:

    • Neuromuscular: Paresthesias (tingling in fingers/toes), muscle cramps, and tetany (involuntary contractions).

    • Cardiac: Prolonged $QT$ interval on ECG, which can lead to Torsades de Pointes or heart failure.

• Approach to the Diagnosis

  • Standard Sequence:

    1. Confirm hyper/hypocalcemia with a repeat test and correct for albumin levels.

    2. Measure Serum Intact PTH to determine if the disorder is "PTH-mediated."

    3. Measure Vitamin D metabolites ($25(OH)D$ and $1,25(OH)_{2}D$) and phosphorus to narrow the differential.

    4. Evaluate renal function (Creatinine/BUN) and magnesium levels.

• Work up and Expected Lab Results

  • Primary Hyperparathyroidism: High $Ca$, High/Inappropriately Normal $PTH$, Low $Phosphorus$, High $1,25(OH)_{2}D$.

  • Humoral Malignancy: High $Ca$, Low/Suppressed $PTH$, High $PTHrP$.

  • Hypoparathyroidism: Low $Ca$, Low/Absent $PTH$, High $Phosphorus$.

  • Vitamin D Deficiency: Low/Normal $Ca$, High $PTH$, Low/Normal $Phosphorus$, Low $25(OH)D$.

• Treatment

  • Hypercalcemia:

    • Acute: Aggressive hydration with $0.9\%$ NaCl (4-6 L/day) to enhance renal calcium clearance. Use IV bisphosphonates (Zoledronic acid/Pamidronate).

    • Adjunct: Calcitonin (subcutaneous) for rapid, short-term reduction (48h max due to tachyphylaxis).

  • Hypocalcemia:

    • Acute/Emergency: IV Calcium Gluconate (1-2g over 10-20 min). Monitor with telemetry due to risk of arrhythmias.

    • Chronic: High-dose oral calcium (carbonate or citrate) and active Vitamin D (Calcitriol) to bypass the need for PTH-mediated renal activation.

• Clinical Pearls

  • Albumin Correction Formula: $Corrected\, Ca = (0.8 \times (4.0 - Measured\, Albumin)) + Measured\, Total\, Ca$.

  • The Magnesium Link: Severe hypomagnesemia ( < 1.0\, mg/dL) induces both PTH resistance and blocks PTH secretion. Hypocalcemia will not resolve until magnesium is replaced.

  • Physical Signs: Chvostek’s (facial twitch on tapping) and Trousseau’s (carpal spasm with BP cuff) signs are highly suggestive of hypocalcemic tetany.

• Summary
  Calcium homeostasis depends on a delicate balance between bone, kidneys, and intestines, regulated by PTH and Vitamin D. Hypercalcemia is often a sign of endocrine dysfunction (pHPT) or serious underlying disease (malignancy), while hypocalcemia primarily presents with neuromuscular irritability and often stems from surgical complications or nutritional deficiencies. Accurate diagnosis relies on the integrated interpretation of ionized calcium, PTH, and Vitamin D levels.